Q-omics provides the consensus-scored ZNF596 profile across patient tissues and cancer cell-line models. ZNF596 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, ZNF596 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, ZNF596 RNA expression shows 19,652 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight PAAD, THCA, and UVM as cancer lineages where ZNF596 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF596 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF596 survival associations across molecular data types. ZNF596 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF596 RNA expression–survival associations across cancer types. High ZNF596 expression shows unfavorable associations in STAD, LGG and LUAD, but favorable associations in PAAD, HNSC and SKCM. The PAAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for ZNF596 RNA expression.
This table summarizes ZNF596 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF596. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF596 shows lower tumor expression in THCA, LUAD, KICH, BRCA, LUSC and HNSC. The THCA box plot shows higher ZNF596 RNA expression in normal versus tumor tissue (log2 FC = −0.524, t-test p < 0.001).
This table shows molecular features associated with ZNF596 in patient tissues and cancer cell lines. In patient samples, ZNF596 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF596 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
